Sino Biological has developed recombinant spike RBD mutant N501Y of new SARS-CoV-2 Variant B.1.1.7 that occurred in the U.K. to support antibody evaluation and vaccination efficacy. SARS-CoV-2 Spike Variant B.1.1.7 Available
Sino Biological has developed recombinant spike RBD mutant N501Y of new SARS-CoV-2 Variant B.1.1.7 that occurred in the U.K. to support antibody evaluation and vaccination efficacy. 
